Detection Of Proteins Expression From Mycobacterium Smegmatis Mc～2 155 Treated With Three Drugs By Two-dimensional Electrophoresis

Objective: The tuberculosis (TB) is one of the main threats of the health. In 1944, streptomycin was administered for the first time to a critically ill TB patient. For the first time, M. tuberculosis could be assailed and beaten into retreat within the human body. The following two decades then witnessed the development of a series of anti-TB drugs including p-aminosalicylic acid (PAS), isonicotinyl hydrazide (INH), pyrazinamide (PZA), D-cycloserine (CS), Ethambutol (EMB), ethionamide (ETH) and rifampin (RIF). Using combination of drugs was effective in controlling TB infections. But in the last few years, along with the increasing number of multi-drug resistant (MDR) TB and the HIV patient, there was a global emergence for the 3 time. The return of tuberculosis which had made the usefulness of combination treatment will be subjected to the challenge and became the tremendous difficulty to the tuberculosis control. Thus, newer and more efficient anti-TB drugs are desperately needed. The unraveling of the M.tuberculosis genome sequence will undoubtedly give new dimensions to anti-TB drug research and help to identify the enzymes/proteins involved in essential biochemical pathways of M. tuberculosis. Comparing to the genome, proteome processes the characters of diversity, and many direction in time and space. It can help to search the drug targets and optimize the chemical compound. To investigate the action mechanism of ethambutol, isoniazid and rifampin, proteomic methods were used to find differential expressed proteins in Mycobacterium smegmatis mc~2 155 that were treated with ethambutol,...